Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: mohamed yi. J Hepatocell Carcinoma. 2024 Mar 4;11:455-461. doi: 10.2147/JHC.S452564. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38463542 Free PMC article.
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. Kaseb AO, et al. Among authors: mohamed yi. J Hepatocell Carcinoma. 2021 Sep 9;8:1129-1145. doi: 10.2147/JHC.S318865. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 34527608 Free PMC article.
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Mohamed YI, et al. Oncotarget. 2022 Dec 6;13:1314-1321. doi: 10.18632/oncotarget.28322. Oncotarget. 2022. PMID: 36473155 Free PMC article.
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: mohamed yi. Oncology. 2023;101(11):730-737. doi: 10.1159/000531870. Epub 2023 Aug 23. Oncology. 2023. PMID: 37467732 Free PMC article.
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.
Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. Morris JS, et al. Among authors: mohamed yi. Hepatology. 2021 Jun;73(6):2278-2292. doi: 10.1002/hep.31555. Epub 2021 Jun 15. Hepatology. 2021. PMID: 32931023 Free PMC article.
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Mohamed YI, et al. Oncotarget. 2021 Apr 13;12(8):756-766. doi: 10.18632/oncotarget.27924. eCollection 2021 Apr 13. Oncotarget. 2021. PMID: 33889299 Free PMC article.
Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma.
Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Kaseb AO, et al. Among authors: mohamed yi. Front Oncol. 2022 Oct 6;12:986305. doi: 10.3389/fonc.2022.986305. eCollection 2022. Front Oncol. 2022. PMID: 36276070 Free PMC article.
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO. Gok Yavuz B, et al. Among authors: mohamed yi. Cancers (Basel). 2023 Oct 7;15(19):4875. doi: 10.3390/cancers15194875. Cancers (Basel). 2023. PMID: 37835569 Free PMC article. Review.
24 results